You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

6 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell
Intent: Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Systemic Anaplastic Large Cell Lymphoma
Sep 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Relapsed or Refractory Hodgkin Lymphoma
Sep 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) with Paclitaxel and Carboplatin - Front-line Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Jul 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Consolidation Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma
Sep 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - T-cell, 
Rare Diseases
Intent: Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Previously Treated Primary Cutaneous Anaplastic Large Cell Lymphoma or Mycosis Fungoides
Sep 2024
Drug
Other Name(s): Avastin® , Mvasi®; Zirabev®; Bambevi®; Abevmy®; Aybintio®; Vegzelma™
Nov 2024